Dr. Elba Etchebehere, nuclear medicine physician and principal investigator at CEPID CancerThera, has just been appointed as a member of the International Advisory Board of The Lancet Medical Imaging & Theranostics, the newest open-access scientific journal from the The Lancet.
The journal, launched in February 2026, will publish its first issue in August 2026 and will focus on innovative, high clinical-impact research in modalities such as Nuclear Medicine (including PET/CT, SPECT/CT, and Theranostics) and Radiology (including magnetic resonance imaging, ultrasonography, computed tomography, among others).
For the specialist, who is also a professor at the Faculdade de Ciências Médicas da Unicamp (FCM/Unicamp) and president of the Sociedade Brasileira de Medicina Nuclear e Imagem Molecular (SBMN), the appointment is both significant recognition and an opportunity for global impact. “I am honored to receive this invitation,” celebrates Etchebehere.
The role of the new advisor
The journal’s main purpose is to publish novel imaging applications for disease screening, diagnosis, prognosis, and treatment across all medical specialties. Highlighting the importance of creating a scientific publication exclusively focused on these continuous advances, the researcher emphasized the relevance of the journal: “The launch of a high-level journal with this scope by The Lancet group is a landmark for our field; Theranostics and advanced medical imaging are revolutionizing personalized medicine, and having a space dedicated exclusively to high-quality research will certainly accelerate the integration of new technologies into clinical practice.”
Etchebehere will advise the editorial team, led by Editor-in-Chief Ali Landman, on the latest developments and trends in the specialty. Board members will also serve as global ambassadors for the journal, assisting in the recommendation of reviewers, providing feedback on the journal’s development, and mapping major clinical trials and research initiatives worldwide.
The researcher’s presence in the group strengthens the position of leading Brazilian institutions within the international scientific landscape. In this regard, the physician emphasized the collaborative nature of the new publication: “This initiative will bring together international experts around scientific and clinical discussions on the diagnosis, prognosis, and treatment of diseases across different medical specialties. I am grateful for the trust placed in me and for the opportunity to contribute to this important international project, while also representing FCM/Unicamp and SBMN.”
Text: Romulo Santana Osthues
